News

VIPC’s Robert Stolle Announces Plans to Step Down From His Role as President and CEO

As CEO, Bob Stolle led Virginia’s consolidation of several innovation and entrepreneurship programs into the newly established VIPC. This consolidation expanded and coordinated programs that provide support for Virginia’s entrepreneurs, tech startups, research commercialization, regional ecosystems, and new industry sectors such as Advanced Air Mobility and Smart Communities.

“Having the privilege of leading VIPC over the last three years has been the most rewarding experience of my professional career” Stolle said. “VIPC has a staff of exceptionally talented and experienced professionals. I’m very proud of where we are as a team, but I believe this is a good time to pass the baton to the next generation of leadership for innovation in Virginia”.

“The Commonwealth has benefited greatly and will continue to benefit for years to come from Bob’s many years of investing his considerable talents, time, and exemplary service,” said Caren Merrick, Secretary of Commerce and Trade and Vice Chair of VIPC.

“Under Bob’s leadership, VIPC has forged a series of integrated programs to help entrepreneurs bring their technologies to commercialization, whether the technology originates in one of Virginia’s academic institutions or in the private sector. As an entrepreneur myself, I know that these programs make a real difference in the success of our emerging and growing tech enterprise,” said Barbara D. Boyan, PhD, Chair of the VIPC Board of Directors and Executive Director of the Institute for Engineering and Medicine at Virginia Commonwealth University.

Joseph Benevento, Virginia Deputy Secretary of Commerce & Trade, will assume the role of Interim CEO beginning in September, while the VIPC Board recruits a permanent CEO. Bob Stolle will stay on in an advisory role to assist in the transition until at least the end of October.

“I’m very grateful to the VIPC Board of Directors and to the Youngkin Administration for their trust, support, and for the opportunity to serve the Commonwealth of Virginia” Stolle said.

Learn more here.

Recent News

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and

06/02/2026

Contraline Announces $92.5 Million Series B Financing to Advance NES/T Male Contraceptive into Late-Stage Development

Contraline, Inc., a clinical-stage biopharmaceutical company developing novel male contraceptives, today announced the closing of a $92.5 million Series B financing co-led by BVF Partners L.P. and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other new and existing investors. In conjunction with the closing of the Series B financing,

06/02/2026

GEN Names BioHealth Capital Region a Top 3 U.S. Biopharma Cluster for Fourth Year in a Row

The BioHealth Capital Region, spanning Maryland, Virginia, and Washington, D.C., has once again been named one of the nation’s Top 3 biopharma clusters by Genetic Engineering & Biotechnology News (GEN), marking the region’s fourth consecutive year in the Top 3. GEN’s 2026 “Top 10 U.S. Biopharma Clusters” ranking was authored by Alex Philippidis, Senior Business